BioNTech's oncology assets, including BNT327/PM8002, show promising results. Read why I maintain my buy rating on BNTX stock.

Bertram Yuh, MD, MISM, MSHCPM, discussed how single-port robotic surgery has changed treatment paradigms for patients with ...

Malcolm Ethridge, Capital Area Planning Group managing partner, joined CNBC to talk about where the market could go and his ...

NANTES, France, October 17, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced it will be presenting its ...

According to The Insight Partners study on the Radiation Oncology Market is observing significant growth owing to the ...

The global clinical next-generation sequencing (NGS) data analysis market opportunity enjoys a valuation of USD 2.3 Billion in 2023, and it is further projected to expand at a CAGR of 17.4% over the ...

October 7, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news ...

Diakonos’ dendritic cell vaccine represents a unique approach for engaging an immune response against a patient’s cancer.

The global high potency API (HPAPI) contract manufacturing market achieved a market value of USD 8 billion in 2022 and is ...

Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology LONDON – Oct. 21, 2024 – ...

The Swiss market recently demonstrated resilience by rebounding from a weak start, buoyed by the European Central Bank's interest rate cut to 3.25%, which helped lift the SMI index by 0.91% to close ...

AKT1 E17K mutation is a clinically validated oncogene that impacts greater than 40,000 cancer patients per year in the United States, with the highest prevalence in breast, endometrial, and prostate ...